- Identifying the primary site
- Indeterminate or differential diagnosis
- Atypical presentation
- Poorly differentiated tumors
- Limited biopsy tissue
- New primary vs. recurrence
The test uses real-time RT-PCR to measure the expression of 92 genes in a patient’s tumor, and classifies the tumor by matching the gene expression pattern of the tumor to a reference database of known tumor types and histological subtypes consisting of 2,206 tumor specimens. Probability scores are then generated by an algorithm.
Breast Cancer Index™ is a prognostic biomarker that provides quantitative assessment of the likelihood of distant recurrence in patients with ER+, LN- breast cancer. EGFR, KRAS, and BRAF Mutation Tests are also available through bioTheranostics.